Chronic activation of endogenous angiotensin‐converting enzyme 2 protects diabetic rats from cardiovascular autonomic dysfunction
Open Access
- 21 March 2012
- journal article
- Published by Wiley in Experimental Physiology
- Vol. 97 (6) , 699-709
Abstract
In this study, we evaluated whether the activation of endogenous angiotensin‐converting enzyme 2 (ACE2) would improve the cardiovascular autonomic dysfunction of diabetic rats. Ten days after induction of type 1 diabetes (streptozotocin, 50 mg kg−1i.v.), the rats were treated orally with 1‐[(2‐dimethylamino)ethylamino]‐4‐(hydroxymethyl)‐7‐[(4‐methylphenyl) sulfonyl oxy]‐9H‐xanthene‐9‐one (XNT), a newly discovered ACE2 activator (1 mg kg−1 day−1), or saline (equivalent volume) for 30 days. Autonomic cardiovascular parameters were evaluated in conscious animals, and an isolated heart preparation was used to analyse cardiac function. Diabetes induced a significant decrease in the baroreflex bradycardia sensitivity, as well as in the chemoreflex chronotropic response and parasympathetic tone. The XNT treatment improved these parameters by ∼76% [0.82 ± 0.09 versus 1.44 ± 0.17 Ratio between changes in pulse interval and changes in mean arterial pressure (ΔPI/ΔmmHg)], ∼85% (−57 ± 9 versus−105 ± 10 beats min‐1) and ∼205% (22 ± 2 versus 66 ± 12 beats min‐1), respectively. Also, XNT administration enhanced the bradycardia induced by the chemoreflex activation by ∼74% in non‐diabetic animals (−98 ± 16 versus−170 ± 9 Δbeats min‐1). No significant changes were observed in the mean arterial pressure, baroreflex tachycardia sensitivity, chemoreflex pressor response and sympathetic tone among any of the groups. Furthermore, chronic XNT treatment ameliorated the cardiac function of diabetic animals. However, the coronary vasoconstriction observed in diabetic rats was unchanged by ACE2 activation. These findings indicate that XNT protects against the autonomic and cardiac dysfunction induced by diabetes. Thus, our results provide evidence for the viability and effectiveness of oral administration of an ACE2 activator for the treatment of the cardiovascular autonomic dysfunction caused by diabetes.Keywords
This publication has 84 references indexed in Scilit:
- Angiotensin-Converting Enzyme 2 Deficiency in Whole Body or Bone Marrow–Derived Cells Increases Atherosclerosis in Low-Density Lipoprotein Receptor −/− MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- ACE2/ANG-(1–7)/Mas pathway in the brain: the axis of goodAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2011
- Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinasesExperimental Physiology, 2011
- Role of blood flow in carotid body chemoreflex function in heart failureThe Journal of Physiology, 2010
- Brain-Selective Overexpression of Human Angiotensin-Converting Enzyme Type 2 Attenuates Neurogenic HypertensionCirculation Research, 2010
- Evidence for Angiotensin-converting Enzyme 2 as a Therapeutic Target for the Prevention of Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Angiotensin II Type 1 Receptor–Mediated Reduction of Angiotensin-Converting Enzyme 2 Activity in the Brain Impairs Baroreflex Function in Hypertensive MiceHypertension, 2009
- Angiotensin-(1-7) and Baroreflex Function in Nucleus Tractus Solitarii of (mRen2)27 Transgenic RatsJournal of Cardiovascular Pharmacology, 2008
- Injections of angiotensin‐converting enzyme 2 inhibitor MLN4760 into nucleus tractus solitarii reduce baroreceptor reflex sensitivity for heart rate control in ratsExperimental Physiology, 2008
- Physiology and immunology of the cholinergic antiinflammatory pathwayJournal of Clinical Investigation, 2007